Jean-Michel Fabre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Michel Fabre has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Jacques Domergue
4 shared publications- Dominique Larrey
Liver Unit, Saint-Eloi Hospital, Montpellier School of Medicine, Montpellier, France
2 shared publications - Jean-Marc Catheline
Department of Digestive Surgery, Centre Hospitalier de Saint-Denis, 2 rue du Docteur Delafontaine, 93200 Saint-Denis, France
2 shared publications Michael Bismuth
2 shared publicationsAbdel Raouf Khiari
1 shared publicationAndr[Eacute] Pellegrin
1 shared publication
Latest Publications
- Open Access
Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review
(1) Background: The management of metastatic esophageal cancer is more often limited to palliative chemotherapy. Limited data are available regarding the role of surgery that remains controversial. The aim of this systematic review is to assess the survival outcome of surgically treated metastatic esophageal cancer patients. (2) Methods: The present systematic review is designed using the PRISMA guidelines and has been registered with PROSPERO (CRD42019140306). Two reviewers independently searched and identified studies dealing with surgery for stage IV esophageal cancer in the Medline and Google Scholar databases between January 2008 and December 2019. (3) Results: Seven retrospective nonrandomized studies, totaling 1756 patients with stage IV esophageal cancer who underwent curative surgery, were included. Our analysis demonstrates a three-year overall survival rate of 23% (CI 95% 17–31) among patients undergoing surgery. Because only two comparative studies were identified, data compilation and relative risk evaluation through meta-analysis were not possible. (4) Conclusions: Multimodality treatment, including surgery in curative intent, seems associated with a significant chance of three-year overall survival. A prospective evaluation of this approach and validation of adequate selection criteria are needed.
Open AccessSurvival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review
(1) Background: The management of metastatic esophageal cancer is more often limited to palliative chemotherapy. Limited data are available regarding the role of surgery that remains controversial. The aim of this systematic review is to assess the survival outcome of surgically treated metastatic esophageal cancer patients. (2) Methods: The present systematic review is designed using the PRISMA guidelines and has been registered with PROSPERO (CRD42019140306). Two reviewers independently searched and identified studies dealing with surgery for stage IV esophageal cancer in the Medline and Google Scholar databases between January 2008 and December 2019. (3) Results: Seven retrospective nonrandomized studies, totaling 1756 patients with stage IV esophageal cancer who underwent curative surgery, were included. Our analysis demonstrates a three-year overall survival rate of 23% (CI 95% 17–31) among patients undergoing surgery. Because only two comparative studies were identified, data compilation and relative risk evaluation through meta-analysis were not possible. (4) Conclusions: Multimodality treatment, including surgery in curative intent, seems associated with a significant chance of three-year overall survival. A prospective evaluation of this approach and validation of adequate selection criteria are needed.
- 1 December 2019
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 156 (6) , 497-506
Prospective, multicentric, comparative study between sleeve gastrectomy and Roux-en-Y gastric bypass, 277 patients, 3 years follow-up
- 1 December 2019
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 156 (6) , 497-506
Prospective, multicentric, comparative study between sleeve gastrectomy and Roux-en-Y gastric bypass, 277 patients, 3 years follow-up
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Since its first description in 2000, Longitudinal Gastrectomy (LG) has become the first surgical procedure in the treatment of morbid obesity in the world, exceeding in numbers Gastric Bypass (GB). GB is considered to have better results regarding long-term weight loss and improvement in co-morbidities. We aimed to demonstrate that LG is non inferior to GB for a composite end point that included more than 50% excess weight loss from the baseline and surgery related complications after a mean follow-up of 36 months. This is a prospective study in morbidly obese patients that tested a two hypotheses composite outcome: the first hypothesis was that after 36 months LG was non-inferior to GB regarding EWL (the predefined margin of non-inferiority was ±15%), and the second hypothesis was the presence of significant difference in post-operative morbidity and mortality. From February 2008 to March 2015 we included 277 patients (91 GB vs 186 LG). The mean age was 41.1 years, 19.2% had a previous bariatric operation, 85.9% were women and the average pre-intervention BMI was 45.3 kg/m2. At baseline there were no significant differences between the GB and LG for age, sex and BMI. The % of patients with EWL > 50% was at 18 months for 82.1% (GB) vs 84.5% (LG), and 79.1 vs. 79.5% respectively at 36 months. The estimated difference in EWL was [−10.5% to 9.8%], confirming the non-inferiority of LG compared to BP. Finally there was a significant less morbidity and mortality for the LG group (GB vs LG, 12.1 vs. 4.8%, one death for LG, P=0.01). This is the first prospective study demonstrating that LG is not inferior to GB for an estimated 10% difference in EWL but with less surgical complications. These results reinforce the choice of LG as surgical procedure for obesity.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Since its first description in 2000, Longitudinal Gastrectomy (LG) has become the first surgical procedure in the treatment of morbid obesity in the world, exceeding in numbers Gastric Bypass (GB). GB is considered to have better results regarding long-term weight loss and improvement in co-morbidities. We aimed to demonstrate that LG is non inferior to GB for a composite end point that included more than 50% excess weight loss from the baseline and surgery related complications after a mean follow-up of 36 months. This is a prospective study in morbidly obese patients that tested a two hypotheses composite outcome: the first hypothesis was that after 36 months LG was non-inferior to GB regarding EWL (the predefined margin of non-inferiority was ±15%), and the second hypothesis was the presence of significant difference in post-operative morbidity and mortality. From February 2008 to March 2015 we included 277 patients (91 GB vs 186 LG). The mean age was 41.1 years, 19.2% had a previous bariatric operation, 85.9% were women and the average pre-intervention BMI was 45.3 kg/m2. At baseline there were no significant differences between the GB and LG for age, sex and BMI. The % of patients with EWL > 50% was at 18 months for 82.1% (GB) vs 84.5% (LG), and 79.1 vs. 79.5% respectively at 36 months. The estimated difference in EWL was [−10.5% to 9.8%], confirming the non-inferiority of LG compared to BP. Finally there was a significant less morbidity and mortality for the LG group (GB vs LG, 12.1 vs. 4.8%, one death for LG, P=0.01). This is the first prospective study demonstrating that LG is not inferior to GB for an estimated 10% difference in EWL but with less surgical complications. These results reinforce the choice of LG as surgical procedure for obesity.
- 10 September 2011
- Published by Springer Nature in Surgical Endoscopy
- Vol. 26 (2) , 402-407
Laparoscopic versus open distal pancreatectomy: a single-institution case-control study
- 10 September 2011
- Published by Springer Nature in Surgical Endoscopy
- Vol. 26 (2) , 402-407
Laparoscopic versus open distal pancreatectomy: a single-institution case-control study
- 1 July 2006
- Published by Elsevier in Annales de Chirurgie
- Vol. 131 (6-7) , 415-420
Chirurgie laparoscopique : les recommandations des sociétés savantes spécialisées en 2006, SFCL–SFCE
- 1 July 2006
- Published by Elsevier in Annales de Chirurgie
- Vol. 131 (6-7) , 415-420
Chirurgie laparoscopique : les recommandations des sociétés savantes spécialisées en 2006, SFCL–SFCE
- 1 September 2002
- Published by Springer Nature in Surgical Endoscopy
- Vol. 16 (9) , 1358-1361
Is laparoscopic left pancreatic resection justified?
We reviewed our experience of laparoscopic left pancreatectomy to establish the feasibility of this approach and the characteristics of the operating procedure. Thirteen patients with a mean age of 60 years were deemed for a left pancreatectomy. Preoperative diagnoses were: nine mucinous cystadenoma and one insulinoma, intraductal mucinous ectasia, chronic pancreatitis with ductal stenosis, and distal pancreatic tumor. Operative mortality was nil. Two patients required conversion for bleeding from splenic vein injuries leading to a splenectomy in one case. The spleen was preserved in 10 cases. Postoperative course was uneventful in nine cases. Four patients experienced postoperative complications: one pancreatic fistula, two liquid cysts on the pancreatic margin, and one reoperation for bleeding from a trocar port. Length of stay ranged from 5 to 22 days. These preliminary results confirm that in selected cases laparoscopic resection of the left pancreas is feasible and safe.
- 1 September 2002
- Published by Springer Nature in Surgical Endoscopy
- Vol. 16 (9) , 1358-1361
Is laparoscopic left pancreatic resection justified?
We reviewed our experience of laparoscopic left pancreatectomy to establish the feasibility of this approach and the characteristics of the operating procedure. Thirteen patients with a mean age of 60 years were deemed for a left pancreatectomy. Preoperative diagnoses were: nine mucinous cystadenoma and one insulinoma, intraductal mucinous ectasia, chronic pancreatitis with ductal stenosis, and distal pancreatic tumor. Operative mortality was nil. Two patients required conversion for bleeding from splenic vein injuries leading to a splenectomy in one case. The spleen was preserved in 10 cases. Postoperative course was uneventful in nine cases. Four patients experienced postoperative complications: one pancreatic fistula, two liquid cysts on the pancreatic margin, and one reoperation for bleeding from a trocar port. Length of stay ranged from 5 to 22 days. These preliminary results confirm that in selected cases laparoscopic resection of the left pancreas is feasible and safe.
- 1 June 2001
- Published by Frontiers Media SA in Transplant International
- Vol. 14 (3) , 202-204
Nocardiosis revealed by thyroid abcess in a liver - kidney transplant recipient
Nocardiosis is a life-threatening infection, particularly among immunocompromised patients, which usually affects lungs, skin and central nervous system. We report a case of disseminated nocardiosis revealed by suppurative thyroiditis in a liver-kidney transplant recipient with poor nutritional status at the time of infection. Nocardia Asteroides was isolated from fine-needle aspiration material of the thyroid abscess. Clinical manifestations resolved after surgical drainage of the thyroid abscess, prolonged antibiotherapy and diminution of immunosuppressive regimen. Clinicians should be aware of this entity, as Nocardia Asteroides may need more than 5 days of culture to be isolated.
- 1 June 2001
- Published by Frontiers Media SA in Transplant International
- Vol. 14 (3) , 202-204
Nocardiosis revealed by thyroid abcess in a liver - kidney transplant recipient
Nocardiosis is a life-threatening infection, particularly among immunocompromised patients, which usually affects lungs, skin and central nervous system. We report a case of disseminated nocardiosis revealed by suppurative thyroiditis in a liver-kidney transplant recipient with poor nutritional status at the time of infection. Nocardia Asteroides was isolated from fine-needle aspiration material of the thyroid abscess. Clinical manifestations resolved after surgical drainage of the thyroid abscess, prolonged antibiotherapy and diminution of immunosuppressive regimen. Clinicians should be aware of this entity, as Nocardia Asteroides may need more than 5 days of culture to be isolated.
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A1426
The majority of liver transplant recipients with normal liver enzyme tests (LET) exhibit long term liver graft lesions
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A1426
The majority of liver transplant recipients with normal liver enzyme tests (LET) exhibit long term liver graft lesions
- 1 February 1999
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 165 (1) , 43-48
Management of intraductal papillary mucinous tumours of the pancreas
Objective: To focus attention on the management and outcome of patients with intraductal papillary mucinous tumours of the pancreas. Design: Retrospective study and analysis of published reports. Setting: University hospital, France. Subjects: 111 patients (101 published cases and our own 10 cases) divided in two groups: the first including malignant tumours (n = 46), and the second group benign or in situ tumours (n = 61). In 4 patients the type of tumour was not known. Main outcome measure: Resectability, mortality and recurrence. Results: More men had benign or in situ tumours [48/61 (79%) compared with 28/46 (61%), p = 0.054]. Pancreatitis was more common among benign than malignant tumours [34/61 (58%) compared with 21/46 (46%), p = 0.33]. In group I, 39 patients had diabetes. A total of 107 patients were operated on: pancreaticoduodenectomy (n = 54, 50%), distal pancreatectomy (n = 25, 23%), total pancreatectomy (n = 4, 4%), bypass (n = 2, 2%). The type of resection was not mentioned in 22 records (21%). Four patients were not operated on because of their poor general condition. The resectability rate was 98% (105/107). Eleven patients had died at the time of publication. Hospital mortality rate was 3% (n = 3), mainly because 2 of the 4 who had total pancreatectomy died. With a median follow‐up of 37 months, recurrence was 5% (n = 5). Conclusion: Intraductal papillary mucinous tumours of the pancreas are well known distinctive pancreatic tumours that are usually intraductal but may develop into invasive carcinoma. They should be resected, and have a good prognosis and low recurrence rate. Copyright © 1999 Taylor and Francis Ltd.
- 1 February 1999
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 165 (1) , 43-48
Management of intraductal papillary mucinous tumours of the pancreas
Objective: To focus attention on the management and outcome of patients with intraductal papillary mucinous tumours of the pancreas. Design: Retrospective study and analysis of published reports. Setting: University hospital, France. Subjects: 111 patients (101 published cases and our own 10 cases) divided in two groups: the first including malignant tumours (n = 46), and the second group benign or in situ tumours (n = 61). In 4 patients the type of tumour was not known. Main outcome measure: Resectability, mortality and recurrence. Results: More men had benign or in situ tumours [48/61 (79%) compared with 28/46 (61%), p = 0.054]. Pancreatitis was more common among benign than malignant tumours [34/61 (58%) compared with 21/46 (46%), p = 0.33]. In group I, 39 patients had diabetes. A total of 107 patients were operated on: pancreaticoduodenectomy (n = 54, 50%), distal pancreatectomy (n = 25, 23%), total pancreatectomy (n = 4, 4%), bypass (n = 2, 2%). The type of resection was not mentioned in 22 records (21%). Four patients were not operated on because of their poor general condition. The resectability rate was 98% (105/107). Eleven patients had died at the time of publication. Hospital mortality rate was 3% (n = 3), mainly because 2 of the 4 who had total pancreatectomy died. With a median follow‐up of 37 months, recurrence was 5% (n = 5). Conclusion: Intraductal papillary mucinous tumours of the pancreas are well known distinctive pancreatic tumours that are usually intraductal but may develop into invasive carcinoma. They should be resected, and have a good prognosis and low recurrence rate. Copyright © 1999 Taylor and Francis Ltd.